Testimony of the Endocrine Society Submitted to the Food and Drug Administration Clinical Chemistry and Clinical Toxicology Devices Panel
"Finally, patients need guidance on using unverified CGM data safely and effectively. FDA’s approval of this change would enable Dexcom to offer patient support and education on the best ways to use unverified CGM data in real time. It would also allow clinicians to offer cogent advice on how to use the data safely and effectively without verification and for Dexcom to offer appropriate support to clinicians around this important topic. "
Read the Full Testimony
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.
